Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

Clara De Simone; Francesca Perino; Giacomo Caldarola; Magda D'Agostino; Ketty Peris

doi:10.1177/0300060515593250

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

J Int Med Res. 2016 Sep;44(1 suppl):67-71. doi: 10.1177/0300060515593250.

Authors

Clara De Simone¹, Francesca Perino², Giacomo Caldarola², Magda D'Agostino², Ketty Peris²

Affiliations

¹ Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy clara.desimone@rm.unicatt.it.
² Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.

Abstract

Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.

Keywords: Antitumour necrosis factor-α agents; comorbidities; etanercept; psoriasis; psoriatic arthritis.